Please assess the completion status of the following clinical trial:

Trial Title: Study of Vioxx and Radiation Therapy for Brainstem Glioma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed infiltrating lesion involving the pons and an MRI pattern of diffuse infiltration, that is not focal. The tumor may extend beyond the boundary of the pons.~* MRI of the brain with or without gadolinium within 4 weeks of starting therapy.~* Clinical history \< 6 months duration~* Children \>3 years of age and adults \>18 years of age~* Treatment to begin within 6 weeks of diagnosis.~* Written informed consent~* Performance status: ECOG 0,1,2 or equivalent Lansky Play Performance Scale.~* All patients must have adequate bone marrow function (ANC\>1000, platelets \>100,000, SGPT \< 2.5x ULN) and renal function (creatinine clearance \>50/ml/min/1.73 m2 or age-adjusted serum creatinine \< 3x ULN)~  * MRI of the spine within 4 weeks of starting therapy.~Exclusion Criteria:~* Pregnancy. All participants who are of child-bearing age must agree to use a method of birth control/pregnancy prevention.~* Bilirubin \> 3x ULN.~* History of gastrointestinal bleeding.~* History of GI perforation due to ulcerative disease.~* Patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs)~* Prior therapy (Dexamethasone is not considered therapy.)~* Prior malignancy~* Metastasis to the spine.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Vioxx MTD (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).